Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:chemical_formula |
C22 H30 N4 O5 S
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:developed_by |
NS Pharma
|
| gptkbp:effective_date |
FDA approved
|
| https://www.w3.org/2000/01/rdf-schema#label |
Viltolarsen
|
| gptkbp:marketed_as |
Viltepso
|
| gptkbp:mechanism_of_action |
exon skipping
|
| gptkbp:route_of_administration |
subcutaneous injection
|
| gptkbp:targets |
exon 53 of the dystrophin gene
|
| gptkbp:used_for |
gptkb:Duchenne_muscular_dystrophy
|
| gptkbp:bfsParent |
gptkb:Sarepta_Therapeutics
|
| gptkbp:bfsLayer |
5
|